- Home
- WNW vs MYNZ Comparison
WNW vs MYNZ Comparison
Compare WNW & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- MYNZ
- Stock Information
- Founded
- WNW 2015
- MYNZ 2021
- Country
- WNW China
- MYNZ Germany
- Employees
- WNW N/A
- MYNZ N/A
- Industry
- WNW Catalog/Specialty Distribution
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- WNW Consumer Discretionary
- MYNZ Health Care
- Exchange
- WNW Nasdaq
- MYNZ Nasdaq
- Market Cap
- WNW 5.3M
- MYNZ 5.5M
- IPO Year
- WNW 2020
- MYNZ 2021
- Fundamental
- Price
- WNW $1.83
- MYNZ $1.40
- Analyst Decision
- WNW
- MYNZ Buy
- Analyst Count
- WNW 0
- MYNZ 2
- Target Price
- WNW N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- WNW 82.8K
- MYNZ 119.4K
- Earning Date
- WNW 07-07-2025
- MYNZ 07-07-2025
- Dividend Yield
- WNW N/A
- MYNZ N/A
- EPS Growth
- WNW N/A
- MYNZ N/A
- EPS
- WNW 9.06
- MYNZ N/A
- Revenue
- WNW $158,485.00
- MYNZ $893,991.00
- Revenue This Year
- WNW N/A
- MYNZ $26.06
- Revenue Next Year
- WNW N/A
- MYNZ $4.97
- P/E Ratio
- WNW $0.20
- MYNZ N/A
- Revenue Growth
- WNW N/A
- MYNZ N/A
- 52 Week Low
- WNW $0.95
- MYNZ $1.34
- 52 Week High
- WNW $70.00
- MYNZ $22.40
- Technical
- Relative Strength Index (RSI)
- WNW 51.15
- MYNZ 26.61
- Support Level
- WNW $1.71
- MYNZ $1.35
- Resistance Level
- WNW $2.05
- MYNZ $1.46
- Average True Range (ATR)
- WNW 0.19
- MYNZ 0.12
- MACD
- WNW 0.03
- MYNZ 0.02
- Stochastic Oscillator
- WNW 49.25
- MYNZ 9.27
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.